The Center for Medicare and Medicaid Innovation today announced a new payment model for Medicare Part D and Medicare Advantage drug plans beginning January 2020, which will test new incentives for plans, patients and providers to choose drugs with lower list prices. Plans participating in the voluntary five-year model will take on greater risk for spending in the catastrophic phase of Part D and share in any resulting savings to federal reinsurance subsidy costs. The model also includes a Part D rewards and incentives program and other tools to help plans control drug costs and enrollees choose drugs with lower list prices. Also today, the Centers for Medicare & Medicaid Services announced changes to the MA Value-Based Insurance Design model for calendar year 2020, which will allow plans to provide reduced cost sharing and additional supplemental benefits to enrollees based on condition and/or socioeconomic status; bolster rewards and incentives for beneficiaries to improve their health; and increase access to telehealth services. 
 

Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
The Centers for Medicare & Medicaid Services today issued a final rule that would increase Medicare rates by a net 2.3% in fiscal year 2027, compared with…
Headline
The Centers for Medicare & Medicaid Services July 27 released its Contract Year 2025 Part C and Part D Program Audit and Enforcement Report, outlining key…
Headline
The Centers for Medicare & Medicaid Services July 22 released implementation guidance following a district court ruling July 16 that…
Headline
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …
Headline
The Centers for Medicare & Medicaid Services has released an updated FAQ on Protecting Access to Medicare Act private payer data reporting. The deadline is…